Europäische Union - Tschechisch - EMA (European Medicines Agency)

astrazeneca ab - budesonide, formoterol fumarate dihydrate, glycopyrronium bromide - plicní onemocnění, chronická obstrukční - léky na obstrukční onemocnění dýchacích cest, - riltrava aerosphere is indicated as a maintenance treatment in adult patients with moderate to severe chronic obstructive pulmonary disease (copd) who are not adequately treated by a combination of an inhaled corticosteroid and a long-acting beta2 agonist or combination of a long-acting beta2 agonist and a long-acting muscarinic antagonist (for effects on symptoms control and prevention of exacerbations see section 5.

Tschechische Republik - Tschechisch - SUKL (Státní ústav pro kontrolu léčiv)

astrazeneca ab, södertälje array - 5362 budesonid; 14188 dihydrÁt formoterol-fumarÁtu - suspenze k inhalaci v tlakovém obalu - 160mcg/4,5mcg - formoterol a budesonid

Tschechische Republik - Tschechisch - SUKL (Státní ústav pro kontrolu léčiv)

astrazeneca ab, södertälje array - 5362 budesonid; 14188 dihydrÁt formoterol-fumarÁtu - suspenze k inhalaci v tlakovém obalu - 80mcg/2,25mcg - formoterol a budesonid

Tschechische Republik - Tschechisch - SUKL (Státní ústav pro kontrolu léčiv)

astrazeneca ab, södertälje array - 5362 budesonid; 14188 dihydrÁt formoterol-fumarÁtu - prášek k inhalaci - 160mcg/4,5mcg - formoterol a budesonid

Tschechische Republik - Tschechisch - SUKL (Státní ústav pro kontrolu léčiv)

astrazeneca ab, södertälje array - 5362 budesonid; 14188 dihydrÁt formoterol-fumarÁtu - prášek k inhalaci - 320mcg/9mcg - formoterol a budesonid

Tschechische Republik - Tschechisch - SUKL (Státní ústav pro kontrolu léčiv)

astrazeneca ab, södertälje array - 5362 budesonid; 14188 dihydrÁt formoterol-fumarÁtu - prášek k inhalaci - 80mcg/4,5mcg - formoterol a budesonid

Tschechische Republik - Tschechisch - SUKL (Státní ústav pro kontrolu léčiv)

astrazeneca ab, södertälje array - 12077 goserelin-acetÁt - implantát v předplněné injekční stříkačce - 10,8mg - goserelin

Europäische Union - Tschechisch - EMA (European Medicines Agency)

astrazeneca ab - durvalumab - karcinom, plicní jiná než malobuněčná - antineoplastická činidla - non-small cell lung cancer (nsclc)imfinzi as monotherapy is indicated for the treatment of locally advanced, unresectable non small cell lung cancer (nsclc) in adults whose tumours express pd-l1 on ≥ 1% of tumour cells and whose disease has not progressed following platinum based chemoradiation therapy (see section 5. imfinzi in combination with tremelimumab and platinum-based chemotherapy is indicated for the first-line treatment of adults with metastatic nsclc with no sensitising egfr mutations or alk positive mutations. small cell lung cancer (sclc)imfinzi in combination with etoposide and either carboplatin or cisplatin is indicated for the first-line treatment of adults with extensive-stage small cell lung cancer (es-sclc). biliary tract cancer (btc)imfinzi in combination with gemcitabine and cisplatin is indicated for the first line treatment of adults with unresectable or metastatic biliary tract cancer (btc). hepatocellular carcinoma (hcc)imfinzi in combination with tremelimumab is indicated for the first line treatment of adults with advanced or unresectable hepatocellular carcinoma (hcc).

Europäische Union - Tschechisch - EMA (European Medicines Agency)

astrazeneca ab - nirsevimab - imunitní séra a imunoglobuliny, - beyfortus is indicated for the prevention of respiratory syncytial virus (rsv) lower respiratory tract disease in neonates and infants during their first rsv season. beyfortus should be used in accordance with official recommendations.

Tschechische Republik - Tschechisch - SUKL (Státní ústav pro kontrolu léčiv)

astrazeneca ab, södertälje array - 12077 goserelin-acetÁt - implantát v předplněné injekční stříkačce - 3,6mg - goserelin